Company
Johnson & Johnson
NYSE:JNJ
Johnson & Johnson is a diversified healthcare products company. The company is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through two segments: Pharmaceutical and MedTech.
152 stories · page 1 of 2
Johnson & Johnson talcum powder settlement among largest ever
Johnson & Johnson's agreement to settle thousands of cases alleging its talcum powder causes cancer would be among the largest ever in real terms
Johnson & Johnson to eye up IPO market with consumer brand spin-off
Johnson & Johnson is set to spin off its consumer business Kenvue through a float on the NYSE
Johnson & Johnson offers billions to settle baby powder lawsuits
The company has offered to pay out US$8.9bn to settle lawsuits claiming its baby powder causes cancer
Johnson & Johnson loses Supreme Court challenge to pelvic mesh settlement
J&J had appealed a US$302mln judgment in a lawsuit brought by the state of California
Johnson & Johnson reaches $205M settlement in Australian pelvic mesh class action
The settlement, which Shine Lawyers said was the largest settlement in a product liability class action in Australian history, follows multiple court proceedings involving more than 11,000 claimants, the pharmaceutical giant, and its subsid
Johnson & Johnson to discontinue selling its talc-based baby powder in 2023
Due to a barrage of legal challenges and 'misinformation' about product's safety, J&J announced in 2020 it would no longer sell its baby powder in North America and the US
FTSE 100 finishes higher although Wall Street mixed after Netflix flop
At the London close, the UK blue-chip index was 27.94 points or 0.37% higher at 7,629.22, much nearer the session peak of 7,637.87 than the day’s early low of 7,590.62
Johnson & Johnson switches Dutch plant away from Covid vaccine - report
Major customers for the vaccine including the African Union and Covax, the organisation focused on supplying vaccines equally around the world,
J&J puts talc claims subsidiary into bankruptcy
J&J is facing litigation from tens of thousands of people alleging that its talc products contain asbestos and can cause cancer
Archive
Wall Street rallies at the close to finish well in the green
"Having reversed all its Monday losses in yesterday’s session, US markets have continued to move higher in early trade," said Michael Hewson, chief market analyst at CMC Markets
Johnson & Johnson COVID-19 vaccine has possible link to very rare cases of unusual blood clots, says EU regulator
The European Medicines Agency stated that these events should be listed as very rare side effects of the jab
Johnson & Johnson delays COVID-19 vaccine rollout in Europe as US authorities investigate blood clots
The authorities said this decision was taken “out of an abundance of caution” while investigations are ongoing
Archive
Wall Street ends mixed amid new vaccine worries, tech outperformance
JNJ stock lost more than 1% to close at $159.56 Tuesday after the CDC and FDA recommended a pause in the use of its coronavirus vaccine
Wall Street enjoys banner day as Biden signs $1.9T coronavirus relief bill
Data for the week to March 6 showed 712,000 Americans filed for unemployment, down from 754,000 the previous week and below estimates of 725,000
Johnson & Johnson receives US approval for COVID-19 vaccine, to test it on babies
The authorisation is expected to boost the country's immunisation programme
Johnson & Johnson one-jab Covid-19 vaccine set for US approval
Johnson & Johnson said its vaccine was also effective at preventing asymptomatic infections
Johnson & Johnson submits one-shot coronavirus vaccine for US approval
Johnson & Johnson’s target is to administer one billion doses of the vaccine worldwide in 2021
Johnson & Johnson says one-dose COVID-19 vaccine candidate is 66% effective
The jab fell short of its competitors in terms of protection but it only needs one shot to work
Coronavirus: What sets Johnson & Johnson’s vaccine apart from those already in circulation
There is much anticipation for data on the company's candidate even though some competitors have been rolled out in several countries of the world
Archive
Wall Street teeters around the flatline with impeachment proceedings underway
Traders tried to plot a course as US lawmakers in the House of Representatives kicked off a debate on fresh impeachment charges against Trump
Johnson & Johnson starts new UK COVID-19 vaccine trial with 6,000 participants
The pharma giant is looking to see whether two doses can protect patients for longer
Johnson & Johnson second on the list of COVID-19 vaccine setbacks, markets remain calm
Investors seem to have adjusted to the ups and downs of vaccine development, though they are hoping trials can resume soon
Johnson & Johnson halts COVID-19 vaccine trials after unexplained illness
It is not clear whether the individual received a study treatment or a placebo
Archive
US stocks close sharply lower as tech stock continue retreating
The S&P 500, Dow and Nasdaq are down 7.5%, 5.9% and 9.7%, respectively, for the month
US prepares for potential human challenge study for COVID-19 vaccine
Government researchers are developing a strain of the virus that would be used in trials where healthy participants get infected
Johnson & Johnson slapped with $8B verdict in lawsuit over antipsychotic drug Risperdal: Media Reports
A Philadelphia jury sided with 26-year-old Nicholas Murray who argued the healthcare giant downplayed the risks of male breast growth
Buds & Duds: Cannabis stocks in the green; CB2 Insights gets boost from former Johnson & Johnson executive
Also on the move were Cannvas MedTech, Harvest Health & Recreation, Canopy Growth and Choom
Archive
NA Proactive news snapshot: Cannvas MedTech, RYAH Medtech, Constantine Metal Resources, Bragg Gaming Group …
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
CB2 Insights names former Johnson & Johnson executive to its board of directors
Peter Cummins worked for more than two decades at Johnson & Johnson in a variety of executive roles
Investments and investor services
LATE MOVERS: Netflix sinks on disappointing guidance; Qualcomm and Apple settle royalty battle
Also moving Tuesday were Bank of America, Johnson & Johnson, JB Hunt and UnitedHealth
Could psychedelic medicine be the new cannabis?
Recent developments have indicated that new treatments derived from these mind-altering substances are garnering new attention from the investment community
Coverage of Geron kicks off at BTIG with a Buy rating
BTIG analyst Thomas Shrader suggests the stock has been 'left for dead' unfairly
MeiraGTx surges on collaboration with J&J unit on retinal diseases
The arrangement calls for cooperation in clinical development and preclinical programs
Late Movers: Arconic tumbles as board decides against sale, scuttling potential deal with Apollo
Other stocks that moved included Stanley Black & Decker, eBay, Johnson & Johnson and Halliburton
Investments and investor services
EARLY MOVERS: Jack in the Box shares pop on its possible sale
Goldman Sachs shares hit by Malaysian charges; Johnson & Johnson reels from asbestos scandal
Investments and investor services
EARLY MOVERS: Neurocrine Biosciences stock slumps after Tourette drug test fails
Mallinckrodt shares fall after its painkiller treatment was declined by the US Food and Drug Administration
ShareRoot granted ASX trading halt pending capital raising announcement
The halt will remain until Friday, November 16, or when an announcement is released to the market.
Hardware & electrical equipment
ShareRoot increases the Social Science takings amid MediaConsent interest
The consumer data security provider is aiming to grow revenue and reduce spending in the coming year.
Investments and investor services
Johnson & Johnson third-quarter results beat estimates; raises guidance for 2018
Company's sterling performance relied on its pharmaceutical, consumer and medical device businesses
PRE-MARKET MOVERS: Johnson & Johnson nudges higher after it beats forecasts but UnitedHealth Group shares drop
Also in the frame in nUS pre-market deals is investment banking behemoth Goldman Sachs and Carbonite Inc
Johnson & Johnson ordered to pay US$4.7bn in damages to women in talc cancer case
The women alleged J&J knew its talc contained asbestos since the 1970s and covered up the evidence
J&J hit with US$21.7mln verdict in second talcum powder-cancer trial
The New Jersey-based health care giant lost a second trial linking baby powder use to deadly asbestos cancer
Pharma sales turbocharge Johnson & Johnson’s first-quarter earnings beat
Results exceeded Wall Street expectations for earnings and revenue
Johnson & Johnson, Imerys may face more suits related to baby powder, Reuters Says
Two companies were ordered to pay a total of US117mln